KR20230015346A - Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료 - Google Patents

Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료 Download PDF

Info

Publication number
KR20230015346A
KR20230015346A KR1020227040515A KR20227040515A KR20230015346A KR 20230015346 A KR20230015346 A KR 20230015346A KR 1020227040515 A KR1020227040515 A KR 1020227040515A KR 20227040515 A KR20227040515 A KR 20227040515A KR 20230015346 A KR20230015346 A KR 20230015346A
Authority
KR
South Korea
Prior art keywords
carbonyl
amino
pyrazolo
pyrimidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227040515A
Other languages
English (en)
Korean (ko)
Inventor
클레어 랑리쉬
돌카 토마스
스테파니 울프
Original Assignee
프린시피아 바이오파마, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프린시피아 바이오파마, 인코퍼레이티드 filed Critical 프린시피아 바이오파마, 인코퍼레이티드
Publication of KR20230015346A publication Critical patent/KR20230015346A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227040515A 2020-04-22 2021-04-21 Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료 Pending KR20230015346A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
US63/013,784 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
KR20230015346A true KR20230015346A (ko) 2023-01-31

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040515A Pending KR20230015346A (ko) 2020-04-22 2021-04-21 Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료

Country Status (12)

Country Link
US (1) US20230158031A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138836A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522693A (cg-RX-API-DMAC7.html)
KR (1) KR20230015346A (cg-RX-API-DMAC7.html)
CN (1) CN115443136A (cg-RX-API-DMAC7.html)
AU (1) AU2021261327A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020974A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175788A1 (cg-RX-API-DMAC7.html)
IL (1) IL297316A (cg-RX-API-DMAC7.html)
MX (1) MX2022013164A (cg-RX-API-DMAC7.html)
TW (1) TW202206076A (cg-RX-API-DMAC7.html)
WO (1) WO2021216696A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU2012255860C1 (en) * 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
TW201326171A (zh) * 2011-11-03 2013-07-01 Genentech Inc 烷基化哌□化合物
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
US9637486B2 (en) * 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
US9982265B2 (en) * 2014-03-28 2018-05-29 Board Of Regents, The University Of Texas System Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Also Published As

Publication number Publication date
JP2026027386A (ja) 2026-02-18
JP2023522693A (ja) 2023-05-31
AU2021261327A1 (en) 2022-12-22
MX2022013164A (es) 2022-11-30
EP4138836A1 (en) 2023-03-01
CA3175788A1 (en) 2021-10-28
CN115443136A (zh) 2022-12-06
TW202206076A (zh) 2022-02-16
US20230158031A1 (en) 2023-05-25
WO2021216696A1 (en) 2021-10-28
BR112022020974A2 (pt) 2022-12-06
IL297316A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP7840847B2 (ja) Ras阻害剤
EP3105223B1 (en) Pyrazolyl-ureas as kinase inhibitors
CN121487738A (zh) 诱导ras gtp水解的组合物和其用途
JP2026027386A (ja) Btk阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
AU2022228084B2 (en) CRYSTALLINE FORMS OF C21H22Cl2N4O2
US11013741B1 (en) AXL kinase inhibitors and use of the same
D’Cruz et al. Novel Bruton’s tyrosine kinase inhibitors currently in development
AU2014205472B2 (en) Deuterated momelotinib
US20250049810A1 (en) Methods of treating a ras protein-related disease or disorder
JP7701758B2 (ja) 結晶性C21H22Cl2N4O2マロン酸塩
JP2025134877A (ja) BTK阻害剤2-[(3R)-3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを使用する、膜性腎症、IGG4関連疾患、及び抗リン脂質症候群の処置
WO2025255438A1 (en) Methods of treating a ras protein-related disease or disorder
Huang et al. Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
US20160214995A1 (en) Substituted thienotriazolodiazapines
US20260108528A1 (en) Methods of treating a ras protein-related disease or disorder
HK40101405A (en) Crystalline forms of c21h22ci2n4o2
WO2026090245A1 (en) Use of ras inhibitors for treating cancer
WO2011159920A1 (en) [5,6]-dihydro-2h-pyran-2-one derivatives
HK1232532A1 (en) Pyrazolyl-ureas as kinase inhibitors
HK1232532B (en) Pyrazolyl-ureas as kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902